

Anna C Pavlick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/999403/publications.pdf>

Version: 2024-02-01

110
papers

6,485
citations

172457

29
h-index

71685

76
g-index

110
all docs

110
docs citations

110
times ranked

10905
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. Journal of Clinical Oncology, 2022, 40, 9553-9553.	1.6	8
2	Outcomes in patients with resected stage IIIA melanoma treated with adjuvant nivolumab or monitored with observation: A real-world study.. Journal of Clinical Oncology, 2022, 40, e21534-e21534.	1.6	1
3	Current concepts and approaches to merkel cell carcinoma. Archives of Dermatological Research, 2021, 313, 129-138.	1.9	7
4	First-line immunotherapy versus targeted therapy in patients with <i>BRAF</i>-mutant advanced melanoma: a real-world analysis. Future Oncology, 2021, 17, 689-699.	2.4	21
5	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.0	53
6	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology, 2021, 23, 1961-1973.	1.2	66
7	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq1 1 0.784314 rgBT /Overlo activation. Cancer Research, 2021, 81, LB180-LB180.	0.9	3
8	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2656-2666.	1.6	145
9	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innovations, 2021, 1, 100045.	2.4	5
10	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 1692-1704.	10.7	129
11	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunology Research, 2020, 8, 70-80.	3.4	47
12	P865â€...Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€“ independent review committee data update. , 2020, , .		3
13	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
14	Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma. Npj Precision Oncology, 2020, 4, 13.	5.4	20
15	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma. Clinical Cancer Research, 2020, 26, 46-53.	7.0	32
16	TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. Journal of Investigative Dermatology, 2020, 140, 1609-1618.e7.	0.7	14
17	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
18	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. Journal of Clinical Oncology, 2020, 38, 10006-10006.	1.6	32

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.. Journal of Clinical Oncology, 2020, 38, 10033-10033.	1.6	11
20	An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology, 2020, 38, e22050-e22050.	1.6	14
21	Salvage chemotherapy in the treatment of metastatic melanoma after progression on immunotherapy.. Journal of Clinical Oncology, 2020, 38, e22019-e22019.	1.6	0
22	Effect of administration of systemic steroids on survival benefit associated with immunotherapy-induced skin toxicity.. Journal of Clinical Oncology, 2020, 38, e22046-e22046.	1.6	0
23	Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.. Journal of Clinical Oncology, 2020, 38, 10052-10052.	1.6	4
24	Response to immune checkpoint inhibitor (ICI) rechallenge after high-grade immune related adverse events (irAE) in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology, 2020, 38, 10045-10045.	1.6	1
25	Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment.. Journal of Clinical Oncology, 2020, 38, 3077-3077.	1.6	0
26	Using machine learning to predict immunotherapy response in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10010-10010.	1.6	1
27	426â€¦..MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. , 2020, , .		0
28	658â€¦..Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. , 2020, , .		1
29	Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). Scientific Reports, 2019, 9, 10173.	3.3	6
30	MLTI-03. FIRST-LINE STEREOTACTIC RADIOSURGERY COMBINED WITH SYSTEMIC TARGETED AND IMMUNE CHECKPOINT INHIBITOR THERAPY IN MELANOMA PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i14-i15.	0.7	1
31	A phase 2 study of glembatumumab vedotin, an antibodyâ€drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer, 2019, 125, 1113-1123.	4.1	45
32	Frontline Therapy for <i>BRAF</i>-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 564-571.	3.8	42
33	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunology, Immunotherapy, 2019, 68, 897-905.	4.2	38
34	Gamma Knife Radiosurgery and Immunotherapy as Primary Treatment for a Malignant Tumor of the Cranial Base Beginning as Lentigo Maligna: A Case Report. Practical Radiation Oncology, 2019, 9, e608-e612.	2.1	0
35	Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future Oncology, 2019, 15, 349-358.	2.4	34
36	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 including anti-PD-1.. Journal of Clinical Oncology, 2019, 37, 2518-2518.	1.6	71

#	ARTICLE	IF	CITATIONS
37	Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.. Journal of Clinical Oncology, 2019, 37, 2581-2581.	1.6	3
38	Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).. Journal of Clinical Oncology, 2019, 37, 9501-9501.	1.6	70
39	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. Journal of Clinical Oncology, 2019, 37, 9538-9538.	1.6	3
40	The relationship between obesity and immunotherapy: It's complicated.. Journal of Clinical Oncology, 2019, 37, 9562-9562.	1.6	4
41	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 1 0.784314 rgBT /Overlock systemic therapy.. Journal of Clinical Oncology, 2019, 37, 136-136.	1.6	2
42	First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.. Journal of Clinical Oncology, 2019, 37, e13577-e13577.	1.6	0
43	Real-world Merkel cell carcinoma outcomes from a tertiary care center.. Journal of Clinical Oncology, 2019, 37, e14098-e14098.	1.6	0
44	Outcomes in MAGE+ cutaneous squamous cell carcinoma with perineural invasion treated with surgery followed by postoperative radiation therapy.. Journal of Clinical Oncology, 2019, 37, e21043-e21043.	1.6	0
45	Transforming a cancer center into a high reliability organization.. Journal of Clinical Oncology, 2019, 37, 234-234.	1.6	0
46	Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Journal of Translational Medicine, 2018, 16, 82.	4.4	98
47	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600E Mutant Solid Tumors. Clinical Cancer Research, 2018, 24, 22-32.	7.0	30
48	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 2018, 10, .	12.4	425
49	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	27.0	983
50	Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.. Journal of Clinical Oncology, 2018, 36, 3079-3079.	1.6	2
51	Prediction of response and toxicity to immune checkpoint inhibitor therapies (ICI) in melanoma using deep neural networks machine learning.. Journal of Clinical Oncology, 2018, 36, 9529-9529.	1.6	3
52	Gut microbiome and immunotherapy response in melanoma patients.. Journal of Clinical Oncology, 2018, 36, 9575-9575.	1.6	2
53	Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e21585-e21585.	1.6	2
54	Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.. Journal of Clinical Oncology, 2018, 36, e21568-e21568.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Immunotherapy efficacy and safety in elderly cutaneous malignancy patients.. Journal of Clinical Oncology, 2018, 36, e21524-e21524.	1.6	2
56	Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA Dermatology, 2017, 153, 299.	4.1	88
57	MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis. Journal of Investigative Dermatology, 2017, 137, 775-778.	0.7	12
58	A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 47-58.	2.6	34
59	A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 109-109.	1.6	8
60	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology, 2017, 35, 9522-9522.	1.6	6
61	Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.. Journal of Clinical Oncology, 2017, 35, 9559-9559.	1.6	3
62	Targeting EZH2 in acral lentiginous melanoma (ALM).. Journal of Clinical Oncology, 2017, 35, 9534-9534.	1.6	1
63	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.. Journal of Clinical Oncology, 2017, 35, 3017-3017.	1.6	0
64	Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.. Journal of Clinical Oncology, 2017, 35, 9577-9577.	1.6	1
65	Retrospective review of metastatic uveal melanoma (mUM) at NYU Perlmutter Cancer Center (NYU-PCC).. Journal of Clinical Oncology, 2017, 35, e21040-e21040.	1.6	0
66	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Investigational New Drugs, 2016, 34, 439-449.	2.6	86
67	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2016, 34, 4371-4380.	1.6	203
68	Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. Journal of Neuro-Oncology, 2016, 127, 607-615.	2.9	51
69	Sensitivity of plasma BRAF^{mutant} and NRAS^{mutant} cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Molecular Oncology, 2016, 10, 157-165.	4.6	63
70	Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology, 2016, 34, 9525-9525.	1.6	2
71	Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer, 2015, 15, 926.	2.6	2
72	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	47

#	ARTICLE	IF	CITATIONS
73	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. <i>Journal of Medical Genetics</i> , 2015, 52, 231-239.	3.2	17
74	Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 278-287.	3.4	81
75	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	27.0	2,489
76	Dabrafenib for the treatment of melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1075-1084.	0.8	0
77	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	7.0	56
78	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 954-965.	10.7	225
79	Germline genetic determinants of immunotherapy response in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3004-3004.	1.6	6
80	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9006-9006.	1.6	3
81	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9119-TPS9119.	1.6	1
82	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9086-9086.	1.6	1
83	Molecular underpinning of melanoma histologic subtypes in the metastatic setting.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20053-e20053.	1.6	0
84	Integration of melanoma genotyping in clinical care.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9095-9095.	1.6	0
85	Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3030-3030.	1.6	0
86	Dissecting the effect of age on immune response in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9058-9058.	1.6	0
87	The genetic variants in interleukin locus at 1q32.1 as markers of melanoma survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9094-9094.	1.6	0
88	Association of natural killer (NK) cell exhaustion with melanoma progression.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9099-9099.	1.6	0
89	Clinical outcome and CD4+ differentiation in anti-CTLA-4/radiation and anti-CTLA-4/steroid therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3019-3019.	1.6	1
90	Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9019-9019.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2528-2528.	1.6	5
92	Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience.. Journal of Clinical Oncology, 2013, 31, 9041-9041.	1.6	3
93	Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma.. Journal of Clinical Oncology, 2013, 31, 9063-9063.	1.6	9
94	Genetic variation in immunomodulatory genes as markers of melanoma recurrence-free and overall survival.. Journal of Clinical Oncology, 2013, 31, 9021-9021.	1.6	3
95	Impact of age on treatment of primary melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9054-9054.	1.6	0
96	Analysis of plasma-based <i>BRAF</i> and <i>NRAS</i> mutation detection in patients with stage III and IV melanoma.. Journal of Clinical Oncology, 2013, 31, 9023-9023.	1.6	0
97	Intra- and Inter-Tumor Heterogeneity of BRAFV600E Mutations in Primary and Metastatic Melanoma. PLoS ONE, 2012, 7, e29336.	2.5	250
98	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in <i>BRAF</i> ^{V600E} melanoma.. Journal of Clinical Oncology, 2012, 30, 8503-8503.	1.6	19
99	Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.. Journal of Clinical Oncology, 2012, 30, e13598-e13598.	1.6	1
100	The melanoma risk loci as determinants of melanoma prognosis.. Journal of Clinical Oncology, 2012, 30, 8557-8557.	1.6	0
101	MicroRNA alterations associated with <i>BRAF</i> status in melanoma.. Journal of Clinical Oncology, 2012, 30, 8565-8565.	1.6	0
102	Early alterations of microRNA expression to predict and modulate melanoma metastasis.. Journal of Clinical Oncology, 2012, 30, 8550-8550.	1.6	0
103	Prognostic value of mitosis-specific antibodies and computer image analysis in calculating mitotic rate in melanoma.. Journal of Clinical Oncology, 2012, 30, e19003-e19003.	1.6	0
104	TILs in metastatic melanoma tumors: A biomarker for immunotherapy?. Journal of Clinical Oncology, 2012, 30, 8589-8589.	1.6	0
105	Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemotherapy and Pharmacology, 2009, 64, 803-810.	2.3	25
106	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American Journal of Translational Research (discontinued), 2009, 1, 35-43.	0.0	33
107	A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal) Tj ETQq1 1 0.784314 rgBT /Overlock 10 119-125.	1.4	12
108	Innovations in the treatment of melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2 Suppl 3, S-34-7.	4.9	0

#	ARTICLE	IF	CITATIONS
109	Chemotherapy approaches to melanoma. <i>Dermatologic Clinics</i> , 2002, 20, 709-712.	1.7	7
110	Treatment of Metastatic Hormone Refractory Prostate Cancer with Ketoconazole, Hydrocortisone, and Cyclophosphamide. <i>Prostate Journal</i> , 2001, 3, 71-75.	0.2	0